French biotech company Sensorion is set to begin its Phase II clinical trial of SENS-111 to treat acute severe vertigo.

SENS-111 is the first-in-class histamine type 4 receptor antagonist class indicated to treat inner-ear pathologies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It triggers a neuromodulation effect of the sensorineural inner ear cell function and is under development for the symptomatic treatment of vertigo crises or tinnitus.

SENS-111 is a small molecule that can be administered orally, as well as through a standard injection.

The Phase II international, multi-centre, randomised, double-blind and placebo-controlled study will be conducted to test the safety and efficacy of SENS-111 in 207 patients suffering from acute unilateral vestibulopathy.

See Also:

"We are delighted to be able to launch a phase II clinical study of this size with SENS-111 that is a major first in acute severe vertigo."

The patients will be divided into three groups and will receive oral administration of either one of 100mg and 200mg of SENS-111 or placebo for four consecutive days.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study is primarily focused on determining the effect of SENS-111 on the intensity of the vertigo as measured using a visual analog scale.

The secondary goals of the study will be to determine the effect of SENS-111 on the patient’s quality of life and the medium-term recovery of their vestibular function.

Sensorion CEO Laurent Nguyen said: “We are delighted to be able to launch a phase II clinical study of this size with SENS-111 that is a major first in acute severe vertigo.

“Our preclinical results and the activity signals observed in healthy volunteers during the phase Ib trial are enabling us to make rapid progress with this small orally active molecule that aims to treat this highly debilitating pathology, for which physicians lack effective and well-tolerated drugs.”